Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling (original) (raw)

• Bansal R, Magge S, Winkler S . (2003). Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J Neurosci Res 74: 486–493.
  Article CAS PubMed Google Scholar
• Blanckaert VD, Venkateswaran S, Han IS, Kim KH, Griswold MD, Schelling ME . (2002). Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1. Hybrid Hybridomics 21: 153–159.
  Article CAS PubMed Google Scholar
• Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E . (2004). Gefitinib (‘IRESSA’, ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3K/AKT activation. J Cancer Res Clin Oncol 130: 604–614.
  Article CAS PubMed Google Scholar
• Chu CL, Buczek-Thomas JA, Nugent MA . (2004). Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem J 379: 331–341.
  Article CAS PubMed Central PubMed Google Scholar
• Chua CC, Rahimi N, Forsten-Williams K, Nugent MA . (2004). Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 94: 316–323.
  Article CAS PubMed Google Scholar
• Contente S, Kenyon K, Rimoldi D, Friedman RM . (1990). Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 249: 796–798.
  Article CAS PubMed Google Scholar
• Contente S, Yeh TJ, Friedman RM . (2009). Tumor suppressive effect of lysyl oxidase proenzyme. Biochim Biophys Acta 1793: 1272–1278.
  Article CAS PubMed Google Scholar
• Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R et al. (1997). Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31: 223–233.
  Article CAS PubMed Google Scholar
• Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A et al. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478.
  CAS PubMed Google Scholar
• Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A et al. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35–44.
  Article CAS PubMed Central PubMed Google Scholar
• Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222–1226.
  Article CAS PubMed Google Scholar
• Erler JT, Giaccia AJ . (2006). Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66: 10238–10241.
  Article CAS PubMed Google Scholar
• Erler JT, Weaver VM . (2009). Three-dimensional context regulation of metastasis. Clin Exp Metastasis 26: 35–49.
  Article PubMed Google Scholar
• Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y et al. (2006). Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 72: 427–436.
  Article CAS PubMed Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J . (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139–149.
  Article CAS PubMed Google Scholar
• Fannon M, Nugent MA . (1996). Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem 271: 17949–17956.
  Article CAS PubMed Google Scholar
• Forsten-Williams K, Chua CC, Nugent MA . (2005). The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J Theor Biol 233: 483–499.
  Article CAS PubMed Google Scholar
• Gioeli D . (2005). Signal transduction in prostate cancer progression. Clin Sci (Lond) 108: 293–308.
  Article CAS Google Scholar
• Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ . (1999). Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279–284.
  CAS PubMed Google Scholar
• Giri D, Ozen M, Ittmann M . (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159–2165.
  Article CAS PubMed Central PubMed Google Scholar
• Giri D, Ropiquet F, Ittmann M . (1999). Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063–1071.
  CAS PubMed Google Scholar
• Guo Y, Pischon N, Palamakumbura AH, Trackman PC . (2007). Intracellular distribution of the lysyl oxidase propeptide in osteoblastic cells. Am J Physiol Cell Physiol 292: C2095–C2102.
  Article CAS PubMed Google Scholar
• Hajnal A, Klemenz R, Schafer R . (1993). Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 53: 4670–4675.
  CAS PubMed Google Scholar
• Hamalainen ER, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, Pihlajaniemi T et al. (1995). Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 270: 21590–21593.
  Article CAS PubMed Google Scholar
• Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E . (2006). Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem 281: 32217–32226.
  Article CAS PubMed Google Scholar
• He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. (2003). Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278: 21831–21836.
  Article CAS PubMed Google Scholar
• Huggett J, Dheda K, Bustin S, Zumla A . (2005). Real-time RT-PCR normalisation; strategies and considerations. Genes Immun 6: 279–284.
  Article CAS PubMed Google Scholar
• Hurtado PA, Vora S, Sume SS, Yang D, St Hilaire C, Guo Y et al. (2008). Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun 366: 156–161.
  Article CAS PubMed Google Scholar
• Jeay S, Pianetti S, Kagan HM, Sonenshein GE . (2003). Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23: 2251–2263.
  Article CAS PubMed Central PubMed Google Scholar
• Johnson DE, Williams LT . (1993). Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60: 1–41.
  CAS PubMed Google Scholar
• Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI . (1997). New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145. Int J Cancer 71: 1010–1018.
  Article CAS PubMed Google Scholar
• Kagan HM, Li W . (2003). Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88: 660–672.
  Article CAS PubMed Google Scholar
• Kagan HM, Trackman PC . (1991). Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5: 206–210.
  Article CAS PubMed Google Scholar
• Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM . (1991). Lysyl oxidase and rrg messenger RNA. Science 253: 802.
  Article CAS PubMed Google Scholar
• Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM et al. (2002). A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62: 4478–4483.
  CAS PubMed Google Scholar
• Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM . (2000). Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 60: 3904–3908.
  CAS PubMed Google Scholar
• Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K, Nishimura S . (1992). Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine. Proc Natl Acad Sci USA 89: 4879–4883.
  Article CAS PubMed PubMed Central Google Scholar
• Kuivaniemi H, Korhonen RM, Vaheri A, Kivirikko KI . (1986). Deficient production of lysyl oxidase in cultures of malignantly transformed human cells. FEBS Lett 195: 261–264.
  Article CAS PubMed Google Scholar
• Kwabi-Addo B, Ozen M, Ittmann M . (2004). The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11: 709–724.
  Article CAS PubMed Google Scholar
• McPherson RA, Conaway MC, Gregory CW, Yue W, Santen RJ . (2004). The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate 58: 325–334.
  Article CAS PubMed Google Scholar
• Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC et al. (2007). The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res 67: 1105–1112.
  Article CAS PubMed Google Scholar
• Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W et al. (1991). A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 11: 5068–5078.
  Article CAS PubMed Central PubMed Google Scholar
• Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK et al. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955–960.
  Article CAS PubMed Google Scholar
• Nakamoto T, Chang CS, Li AK, Chodak GW . (1992). Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52: 571–577.
  CAS PubMed Google Scholar
• Natke B, Venkataraman G, Nugent MA, Sasisekharan R . (1999). Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation. Angiogenesis 3: 249–257.
  Article CAS PubMed Google Scholar
• Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D et al. (2007). Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117: 2766–2777.
  Article CAS PubMed Central PubMed Google Scholar
• Nugent MA, Edelman ER . (1992). Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry 31: 8876–8883.
  Article CAS PubMed Google Scholar
• Nugent MA, Iozzo RV . (2000). Fibroblast growth factor-2. Int J Biochem Cell Biol 32: 115–120.
  Article CAS PubMed Google Scholar
• Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M . (2001). Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93: 1783–1790.
  Article CAS PubMed Google Scholar
• Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE et al. (2004). The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 279: 40593–40600.
  Article CAS PubMed Google Scholar
• Palamakumbura AH, Sommer P, Trackman PC . (2003). Autocrine growth factor regulation of lysyl oxidase expression in transformed fibroblasts. J Biol Chem 278: 30781–30787.
  Article CAS PubMed Google Scholar
• Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF et al. (2005). Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65: 11429–11436.
  Article CAS PubMed Google Scholar
• Planz B, Wang Q, Kirley SD, Marberger M, McDougal WS . (2001). Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate. J Urol 166: 678–683.
  Article CAS PubMed Google Scholar
• Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S et al. (2003). Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63: 5754–5760.
  CAS PubMed Google Scholar
• Powers CJ, McLeskey SW, Wellstein A . (2000). Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165–197.
  Article CAS PubMed Google Scholar
• Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC . (1998). Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58: 1285–1290.
  CAS PubMed Google Scholar
• Richardson TP, Trinkaus-Randall V, Nugent MA . (1999). Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate. J Biol Chem 274: 13534–13540.
  Article CAS PubMed Google Scholar
• Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M . (2000). Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60: 4245–4250.
  CAS PubMed Google Scholar
• Ropiquet F, Giri D, Lamb DJ, Ittmann M . (1999). FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 162: 595–599.
  Article CAS PubMed Google Scholar
• Samid D, Shack S, Myers CE . (1993). Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288–2295.
  Article CAS PubMed Central PubMed Google Scholar
• Schlessinger J . (2004). Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506–1507.
  Article CAS PubMed Google Scholar
• Shain SA . (2004). Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2. Mol Cancer Res 2: 653–661.
  CAS PubMed Google Scholar
• Smith JA, Madden T, Vijjeswarapu M, Newman RA . (2001). Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62: 469–472.
  Article CAS PubMed Google Scholar
• Trackman PC, Bedell-Hogan D, Tang J, Kagan HM . (1992). Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. J Biol Chem 267: 8666–8671.
  CAS PubMed Google Scholar
• Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH et al. (2001). Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem 276: 22537–22543.
  Article CAS PubMed Google Scholar
• Weber MJ, Gioeli D . (2004). Ras signaling in prostate cancer progression. J Cell Biochem 91: 13–25.
  Article CAS PubMed Google Scholar
• Wesley UV, McGroarty M, Homoyouni A . (2005). Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 65: 1325–1334.
  Article CAS PubMed Google Scholar
• Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC et al. (2007). Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 67: 6278–6285.
  Article CAS PubMed Google Scholar
• Zhang Y, Song S, Yang F, Au JL, Wientjes MG . (2001). Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299: 426–433.
  CAS PubMed Google Scholar
• Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH . (2009). The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 284: 1385–1393.
  Article CAS PubMed Central PubMed Google Scholar